Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FLGT vs NDRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FLGT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

FLGT Overall Winner 6-Pillar Tally: FLGT 5 – 1 NDRA Matrix Metrics: FLGT 6 – 4 NDRA

As of Nov 16, 2026, Fulgent Genetics, Inc. (FLGT) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). FLGT carries a Unified Composite Score of 33.3/100 (SELL) at $24.07 (7.7x Forward P/E, -37.1% operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. FLGT 33.3/100 SELL), FLGT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-37.1% vs. 0.0% operating margin) and revenue trajectory (+7.5% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: FLGT trades in a Markup technical trend (BREAKOUT options phase, RSI 59.0); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FLGT vs NDRA
FLGT NASDAQ Head-to-Head Winner
Fulgent Genetics, Inc. Common Stock
Services-Medical Laboratories
$24.07
-2.37% 1D
Market Cap $689.0M
TTM Revenue $330M
Forward P/E 7.7x
Beta / 30D Vol 1.10β · 110% Vol
Unified Composite Score
33.3 / 100 SELL
Tech 50.0 Fund 32.0 Flow 56.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.8% over 20 days), RSI 59
RSI-14: 59.0 · SMA20: $21.86 · SMA50: $21.47
NDRA NASDAQ
ENDRA Life Sciences Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
+0.23% 1D
Market Cap $6.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.71β · 48% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 35.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.3%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $4.75 · SMA50: $5.32

6-Pillar Scorecard Institutional Category Breakdown (FLGT 5 – 1 NDRA)

Columns: Metric · FLGT · NDRA
1. Valuation Multiples FLGT
Forward P/E 7.7x N/M
Trailing P/E 7.7x N/M
PEG Ratio 1.32x N/M
EV / Revenue 1.9x N/M
2. Growth & Scale FLGT
Revenue Growth (YoY) +7.5% +0.0%
Earnings Growth (YoY) -98.6% +0.0%
TTM Revenue (USD) $330M N/A
Market Cap $689.0M $6.6M
3. Profitability & Quality NDRA
Gross Margin 33.8% N/A
Operating Margin -37.1% 0.0%
Net Profit Margin -27.5% 0.0%
Return on Equity (ROE) -8.7% -152.0%
4. Balance Sheet & Cash Flow FLGT
Cash Generation (TTM) -$1.4M -$8.0M
Cash Flow Margin -0.4% N/A
Net Cash / Leverage $77M Net Cash $104,744 Net Debt (0.26x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FLGT
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 67.5% (13th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat FLGT
OpEx & R&D Intensity 70.9% of Rev ($234M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FLGT (6) vs NDRA (4)
Institutional Metric FLGT NDRA Criterion Row Edge
Market Capitalization
Scale
$689.0M $6.6M Larger Scale FLGT
Trailing P/E Ratio
Valuation
7.7x N/M Lower Multiple FLGT
Forward P/E Ratio
Valuation
7.7x N/M Lower Multiple FLGT
Revenue Growth (YoY)
Growth
+7.5% +0.0% Higher Growth FLGT
Operating Margin (TTM)
Profitability
-37.1% 0.0% Higher Margin NDRA
Net Profit Margin
Profitability
-27.5% 0.0% Higher Margin NDRA
Return on Equity (ROE)
Capital Efficiency
-8.7% -152.0% Higher ROE FLGT
52-Week Range Position
Momentum
60% ($13–$31) 37% ($3–$7) Stronger Trend FLGT
Beta / 30D Volatility
Risk Regime
1.10β · 110% Vol 0.71β · 48% Vol Lower Realized Risk NDRA
Unified Institutional Score
Composite Signal
33.3 / 100 (SELL) 44.7 / 100 (HOLD) Higher Composite NDRA
Trailing 12M Revenue (USD)
Operating Scale
$330M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
33.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.32x PEG · 1.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.4M ($77M Net Cash) -$8.0M ($104,744 Net Debt (0.26x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FLGT +28.28 pp
FLGT: +21.53% · NDRA: -6.75%
3M Horizon FLGT +31.64 pp
FLGT: +29.64% · NDRA: -2.0%
6M Horizon FLGT +70.19 pp
FLGT: +51.89% · NDRA: -18.3%
1Y Horizon FLGT +14.08 pp
FLGT: -18.64% · NDRA: -32.72%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FLGT Revenue NDRA Revenue FLGT Op. Margin NDRA Op. Margin Margin Leader
FY2018 $20M $0M -23.7% -146080.5% FLGT
FY2019 $30M N/A -1.3% N/A FLGT
FY2020 $420M N/A 68.8% N/A FLGT
FY2021 $990M N/A 68.1% N/A FLGT
FY2022 $620M N/A 28.8% N/A FLGT
FY2023 $290M N/A -67.6% N/A FLGT
FY2024 $280M N/A -26.1% N/A FLGT
FY2025 $320M N/A -28.2% N/A FLGT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FLGT BREAKOUT
94d in phase · OBV NEUTRAL
Current IV 67.5%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact FLGT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NDRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NDRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FLGT Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $689.0M market capitalization and -37.1% operating margin.
OpEx & R&D Reinvestment 70.9% of Rev ($234M)
90D Engineering Disclosures 0 Published
NDRA Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $6.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FLGT vs NDRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Fulgent Genetics, Inc. (FLGT) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). FLGT carries a Unified Composite Score of 33.3/100 (SELL) at $24.07 (7.7x Forward P/E, -37.1% operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. FLGT 33.3/100 SELL), FLGT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-37.1% vs. 0.0% operating margin) and revenue trajectory (+7.5% vs. +0.0% YoY). Technical & Structure Timing Caution: FLGT trades in a Markup technical trend (BREAKOUT options phase, RSI 59.0); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FLGT leads the Growth & Scale pillar: FLGT posts +7.5% YoY revenue growth and -98.6% YoY earnings growth on $330M TTM revenue (33.8% gross margin, -37.1% operating margin), compared with NDRA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FLGT cumulative revenue shifted +1500.0% while NDRA shifted N/A. In operating R&D and SG&A reinvestment, FLGT deploys 70.9% of Rev ($234M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NDRA.

FLGT screens cheaper on headline valuation multiples. FLGT trades at 7.7x Forward P/E, 7.7x Trailing P/E, 1.32x PEG, and 1.9x EV/Revenue (-0.4% FCF margin), whereas NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FLGT (-8.7% ROE) versus NDRA (-152.0% ROE) capital efficiency.

In options market volatility and institutional positioning, FLGT carries 67.5% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.10β · 110% Vol realized risk). By comparison, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.